Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Objective To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Design A 12-month, multicenter, randomized, double-masked, active-controlled...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2011-05, Vol.118 (5), p.831-839
Hauptverfasser:	Schmidt-Erfurth, Ursula, MD, Eldem, Bora, MD, Guymer, Robyn, MD, PhD, Korobelnik, Jean-François, MD, Schlingemann, Reinier O., MD, Axer-Siegel, Ruth, MD, Wiedemann, Peter, MD, Simader, Christian, MD, Gekkieva, Margarita, MD, Weichselberger, Andreas, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Biological and medical sciences Choroidal Neovascularization - diagnosis Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Double-Blind Method Drug Administration Schedule Female Fluorescein Angiography Humans Intravitreal Injections Macular Degeneration - diagnosis Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Medical sciences Middle Aged Miscellaneous Ophthalmology Ranibizumab Retina - pathology Retinopathies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!